

INDEX

- Abnormal genes, 17, 20–21, 20f–21f
- Acetylcholine
 anticholinergic agents and, 48f
 dopamine receptor blockade and, 48f
 relationship with dopamine, 47f
 release, 46
- Affective flattening, 5
- Aggression
 mania and, 99, 100f
 symptoms in schizophrenia, 8f, 9
 treatment for, 86, 86f
- Agitation, atypical antipsychotics in, 119f
- Agranulocytosis, 70
- AIDS therapy, 131
- Akathisia, 13
- Alcohol abuse, mania and, 99, 100f
- Allosteric modulators, 24, 27f
- Alogia, 5
- Alpha 1 adrenergic blocking, antipsychotic agents and, 46f, 49, 50f
- Alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA), 23, 26f
- Alpha-7-nicotinic cholinergic agonists, 130
- Alzheimer's disease
 psychosis and, 2, 3t
 Aggressive symptoms and, 8f, 9
 cholinergic deficiency and, 130, 131
 cognitive symptoms and, 6, 7f
 excitotoxicity and, 23, 28, 29f–33f
 positive symptoms and, 4–5, 6f
- Amenorrhea, 16
- Amisulpride, 96, 97f
- Amyotrophic lateral sclerosis, 23
- Anhedonia, 5
- Anticholinergic agents, 46
 acetylcholine and, 48f
- Anticonvulsants
 bipolar combinations and, 119, 120, 122, 123f
 in ion storms, 100f
 as mood stabilizers, 102t, 108, 109, 109t, 110f–114f, 111–113, 115, 115f, 116f
- Antidepressants
 combinations, 122, 123f
 in bipolar disorder, 120, 122
- Antihistaminic properties, of conventional antipsychotic agents, 46f, 49, 49f
- Antipsychotic agents
 atypical drugs (*See Atypical antipsychotic drugs*)
 conventional drugs (*See Conventional antipsychotic drugs*)
 future antipsychotics, 127–132
 future combination chemotherapies, 131–132
 novel neurotransmitter mechanisms, 130–131
 novel serotonergic and dopaminergic mechanisms, 127–129
 other antipsychotics, 127, 128f–129f
 in treatment-resistant schizophrenia, 124–127, 124f–126f
- Anxious self-punishment, 4
- Anxious symptoms, in schizophrenia, 8f, 9–10
- Apathy, 3–4
- Apostasis, blocking, 29–30, 33f, 34f
- Aripiprazole, 96, 96f
- Attentional impairment, 5, 9f
- Attention deficit hyperactivity disorder, 8f, 9
- Atypical antipsychotic drugs, 51–66
 binding to postsynaptic dopamine 2 receptors, 60f
 bipolar combinations and, 120, 123f

138 Index

- Atypical antipsychotic drugs (*continued*)
- in bipolar disorder, 97, 118-119, 119f-122f
 - in clinical practice, 80-86
 - clozapine, 68-70, 69f
 - for cognitive symptoms, 84-85, 84f
 - cytochrome P450 1A2, 76, 76f-77f
 - cytochrome P450 3A4, 77-80, 79f-80f
 - cytochrome P450 2D6, 76, 77f-78f
 - four key dopamine pathways, 52-53
 - for hostility, aggression, and poor impulse control, 86, 86f
 - hypothetical action over time, 90f
 - in ion flux reduction, 122f
 - in manic symptoms of psychotic mania, 118-119, 119f-122f
 - mesocortical pathway, 59-61, 61f-63f
 - mesolimbic pathway, 62, 64
 - for mood disorders, 82-84, 83f
 - in mood stabilization, 118-119, 119f-122f
 - for negative symptoms of schizophrenia, 85-86, 85f
 - nigrostriatal pathway (*See* Nigrostriatal pathway)
 - in nonpsychotic mania, 118-119, 121f, 122f
 - olanzapine, 69f, 72, 73f, 120, 121f-122f
 - pharmacokinetic considerations for, 75-80, 76f-80f
 - for positive symptoms of schizophrenia, 81-82, 82f
 - quetiapine, 69f, 72-73, 74f
 - receptor binding properties of, 87-90, 88f, 90f
 - risperidone, , 70-72, 71f
 - serotonergic control of dopamine release, 52-66, 53f-58f, 61f, 63f-65f
 - serotonin-dopamine antagonism, 52-53, 52f
 - tuberoinfundibular pathway, 61-62
 - ziprasidone, 73-75, 74f-75f
 - Avolition, 5
 - Basal ganglia, dopamine deficiency in, 13
 - Benzamide antipsychotics, 96
 - Benzodiazepines, 117, 123f
 - bipolar combinations and, 119, 122, 123f
 - Biological basis, of schizophrenia, 10-16
 - Bipolar combination treatments, 119-122, 123f
 - Bipolar disorder
 - aggressive symptoms and, 8f, 9
 - brainstorm of ions and, 96-99, 98f-106f
 - depressive symptoms and, 8f, 9
 - lithium in, 102, 102t, 107, 107f-108f, 109f
 - positive symptoms and, 4, 6f
 - Blame, 4
 - BMY-14,802, 130
 - Brain development, early, 16-21, 17f-21f
 - Burnout, 22, 22f
 - Cannabinoid antagonists, 130
 - Carbamazepine, 109t, 112, 115f, 123f
 - Carbonic anhydrase inhibitor, 116f
 - Caspase enzymes, 30
 - Caspase inhibitors, 29
 - Cellular events, during excitotoxicity, 28, 30f-32f
 - Chemotherapies, combination, 131-132
 - Childhood psychosis, 5, 6f, 8f, 9-10
 - Chlorpromazine, 39, 41t
 - Cholecystokinin, 130
 - Chorea, 13
 - Clozapine, 68-70, 69f
 - Cognitive symptoms
 - in schizophrenia, 6, 7f
 - treatment for, 84-85, 84f
 - Conceptual disorganization, 3
 - Conduct disorders, in children, 9
 - Conventional antipsychotic drugs, 39-50, 41t, 51f
 - alpha 1 adrenergic blocking properties, 46f, 49, 50f
 - antihistaminic properties, 46f, 49, 49f
 - blocking all four dopamine pathways, 44-45
 - dopamine 2 receptor blockade, 39, 40f, 41-45, 42f-45f, 59, 59f
 - haloperidol, 41t, 49, 50f-51f
 - hypothetical action over time, 89f
 - icon of, 46f
 - "lead in" atypical antipsychotics, 124, 126f
 - in mood stabilization, 117-118, 117f-118f, 120, 123f
 - muscarinic cholinergic blocking properties of, 45-49, 46f-48f
 - pharmacologic properties of, 45-46, 46f-50f, 49
 - receptor binding properties of, 87f, 88-89, 89f
 - risks and benefits of, 45
 - side effects of, 45-46, 47f, 49, 49f, 50f
 - "top up" atypical antipsychotics, 125, 126f
 - Cross-titration, 124, 124f, 125f
 - Cytochrome P450 1A2, 76, 76f-77f
 - Cytochrome P450 3A4, 77-80, 79f-80f
 - Cytochrome P450 2D6, 76, 77f-78f
 - Dendrites, damage to, 28, 29f
 - Depression. *See also* Antidepressants
 - depressive psychosis, 3-4
 - mania and, 97-99, 98f-99f
 - symptoms in schizophrenia, 8f, 9-10
 - Disorganized-excited psychosis, 3
 - Disorientation, 3
 - Divalproex, 108, 109t, 111-112, 111f-114f, 119-120, 123f
 - Dopamine. *See also* Dopamine 2 receptors
 - acetylcholine release and, 45, 46, 47f-48f
 - hypothesis of positive psychosis symptoms, 10
 - novel mechanisms, 127-128
 - secondary deficiency, 61f
 - stabilizers, 91-96, 91f-96f
 - stimulant, 91f
 - Dopamine 2 receptors
 - binding in nigrostriatal pathway
 - atypical antipsychotics, 60f
 - conventional antipsychotics, 59f

- binding properties, 87–90, 87f–90f
 blockade of, 39–44, 40f–44f, 88–90, 89f–90f, 118f
 dilemma of, 44–45
 hyperprolactinemia and, 44f
 long-term blockade, 43f
 mesocortical pathway, 42f
 negative symptoms and, 42f
 in nigrostriatal pathway, 42f
 pure D2 blocker, 40f
 dopamine system stabilizers, 91–96, 91f–96f
 hit and run actions, 87–90, 87f–90f
 improved positive symptoms and, 62–64
 extrapyramidal symptoms and, 41, 42f–43f, 43, 51, 55–59, 57f–58f
 hyperprolactinemia and, 43–44, 44f, 61–62, 63f–65f
 Dorsolateral prefrontal cortex, 11, 13f, 14f
 D3 receptors, 128
 Drug abuse
 mania and, 99, 100f
 Drug-induced psychoses, 5
 DU-127090, 96
 Dyskinesias, 13
 Dysphoria, 99, 99f
 Dystonia, 13

 Excitatory neurotransmission, 23, 28, 28f, 29f–32f
 Excitement, 3
 Excitotoxicity, 22–23, 29f–32f
 cellular events during, 30f–32f
 glutamate system and, 28, 28f–32f
 Executive functioning, 6
 Extrapyramidal symptoms, 41, 42f–43f, 43, 46, 48f, 118

 Fananserin, 128
 Free radicals
 in excitotoxicity, 31f, 32f, 34f
 scavengers, 29, 34f

 Gabapentin, 113, 116f, 123f
 Galactorrhea, 16
 Gamma-aminobutyric acid (GABA), 109, 110f, 111, 111f, 113, 115f, 116f
 Genetic basis in schizophrenia, 17–21, 20f–21f
 Glutamate
 antagonists, 29, 33f
 production, 24f
 receptors, 23–25, 26f–27f
 removal, 23, 25f
 spectrum of excitation, 29f
 systems, excitotoxic overactivity of, 11
 Glutamatergic neurotransmission, 23–28
 excitotoxicity and glutamate system, 22, 28, 28f–32f
 glutamate receptors, 23–25, 26f–27f
 glutamate removal, 23, 25f
 Glutamine, 24f
 Glutamine synthetase, 24f
 Glycine, 24, 27f
 “Goldilocks” antipsychotics, 91–96
 G proteins, 104f, 107f
 Grandiose expansiveness, 3

 Hallucinations, in schizophrenia, 4
 Haloperidol, 49
 icon, 51f
 structural formula of, 50f
 Hit and run binding, 87–90
 HIV/AIDS therapy, 131
 Hostility
 belligerence, 3
 in schizophrenia, 8f
 symptoms in schizophrenia, 9
 treatment for, 86, 86f
 Huntington’s disease, 20
 Hyperkinetic movement disorders, 13
 Hyperprolactinemia, 43–44, 44f
 pharmacology of, 61–62, 63f–65f
 Hypomania, 97, 98f. *See also* Mania

 Iloperidone, 127–128
 Improved negative symptoms, pharmacology of, 59–61, 61f–63f
 Impulse control, treatment for, 86, 86f
 Inositol monophosphatase, 107
 Ion channels
 ligand-gated, 108, 110f
 voltage-gated (*See* Voltage-gated ion channels)
 Ion flow, normal neuronal, 103f, 106f
 Ion flux
 atypical antipsychotic drugs in, 121f–122f
 unstable moods and, 99, 100f–102f, 106f
 valproic acid and, 111–112, 112f–113f

 Kainate, 23, 26f

 L-745,870, 128
 Lamotrigine, 109t, 112–113, 115f, 123f
 Lazaroids, 30, 34f
 Ligand-gated ion channels, 27f, 28f, 108, 110f
 Lithium, 102, 102t, 107, 107f–109f
 bipolar combinations and, 117f, 119, 119f, 123f
 Long-term potentiation, 23
 Lou Gehrig’s disease, 23
 Low extrapyramidal symptoms, pharmacology of, 55–59, 57f–60f
 Loxapine, 127, 128f
 LU-111,995, 128

140 Index

- Magnesium, 24, 27f
- Mania, 97–101, 102f
 atypical antipsychotics in, 118–119, 119f–122f
 characterization of, 97, 98f
 glutamate excitation and, 29f
 anticonvulsants in, 102t, 108–111, 109t
 mixed state, 99, 99f
 mood stabilizing drugs and (*See* Mood stabilizing drugs)
 other clinical features, 100f
 psychosis associated with, 99, 100f, 102f, 117f, 117–119, 119f, 120f
 rapid cycling, 98f
- Mazapertine, 128
- MDL-100,907, 128
- Mesocortical dopamine pathway, 10–13, 11f, 13f, 14f, 42f
 improved negative symptoms and, 59–61, 61f–63f
- Mesolimbic dopamine pathway, 10, 11f, 12f, 40f
 improved positive symptoms and, 62, 64
- Metabotropic glutamate receptor, 26f
- Mixed state, 99, 99f
- Mood disorders in schizophrenia, treatment for, 82–84, 83f
- Mood-stabilizing drugs, 102–122, 102t, 109t, 123f
 anticonvulsants, 102t, 108–113, 109t, 110f–116f, 115
 atypical antipsychotics, 118–119, 119f–122f
 benzodiazepines, 117, 119, 122, 123f
 bipolar combinations, 119–122, 123f
 carbamazepine, 109t, 112, 115f, 123f
 conventional antipsychotics, 117–118, 117f–118f, 120, 123f
 gabapentin, 113, 116f, 123f
 lamotrigine, 109t, 112–113, 115f, 123f
 lithium, 102, 102t, 107, 107f–109f
 topiramate, 113, 115, 116f
 valproic acid, 109t, 111–112, 111f–114f, 123f
- Muscarinic cholinergic receptors, blockade of, 45–49, 46f–48f
- Negative symptoms, 5f, 5-6, 7f, 9t, 41, 42f, 59–61, 61f–63f
- Nemonapride, 128
- Neurodegeneration
 blocking, 29–30, 33f, 34f
 causes of schizophrenia, 35f
 hypothesis, 21–29
 excitotoxicity, 22–23, 29f–33f
 glutamatergic neurotransmission and, 23–28, 24f–32f
- Neurodevelopmental hypothesis, of schizophrenia, 16–21, 17f–21f
- Neurodevelopmental/neurodegenerative therapy hypothesis, 33, 35f
- Neurokinins, 130
- Neurolepsia, 39
- Neuroleptic antipsychotics, bipolar combinations and, 120, 123f
- Neuroleptic-induced deficit syndrome, 41
- Neuroleptic-induced tardive dyskinesia, 14
- Neuroleptic malignant syndrome, 45
- Neurons
 migration of, 16, 17f, 18f
 neuroprotection, 29f
- Neurotensin antagonists, 130
- Neurotransmission, glutamate, 23–28, 24f–32f
- NGD-94-4, 128
- Nigrostriatal dopamine pathway, 13–14, 15f
 dopamine 2 receptor blockage in, 41, 42f, 43, 43f
 pharmacology of low extrapyramidal symptoms, 55–59, 53f–60f
 serotonin-dopamine interactions in, 53–54, 53f–56f
- N-methyl-D-aspartate (NMDA), 23–28, 26f, 27f, 28f, 29, 33f
- Olanzapine, 69f, 72, 73f, 120, 121f–122f
- OPC14523, 130
- OPC-14597, 96
- Organic dementias, 5, 9
- OSU-6162, 96
- Panic, 29f
- Paranoid projection, 3
- Paranoid psychosis, 3
- Parkinson's disease, 13, 23, 41
- Partial agonist action, 95
- PCP site, 25, 27f
- Perospirone, 127, 129f
- Phosphatidyl inositol, 105f, 107
- PNU-101,387G, 128
- Polyamines, 24, 27f
- Positive symptoms
 pharmacology of, 62–64
 in psychosis, 9t
 in schizophrenia, 4–5, 5f, 6f, 9t, 10, 11f–12f, 40f
- Postsynaptic serotonin 2A receptors, 52–62, 52f–59f, 61f–65f, 64
- Precamol, 96
- Presymptomatic treatment, in schizophrenia, 30, 33
- Prolactin
 conventional antipsychotic drugs and, 43–44, 44f, 64f
 dopamine inhibition of, 63f
 elevated level, 15f, 16
 serotonin 2A antagonism and, 61–62, 65f
 serotonin stimulation of, 64f
- Psychosis
 associated disorders, 2, 3t
 clinical description of, 2–4
 defining symptom in, 2, 2t

- depressive psychosis, 3–4, 8f, 9–10
 related disorders, 2t
 disorganized-excited, 3
 mania and, 99, 100f, 102f, 117f, 117–119, 119f, 120f
 negative symptoms in, 5f, 5–6, 7f, 9t
 paranoid psychosis, 3
 positive symptoms in, 4–5, 5f–6f, 9t
 Psychotomimic agent phencyclidine (PCP), 25, 27f, 130
- Quetiapine, 69f, 72–73, 74f
- Rapid cycling, 98f, 99, 107, 111, 114f
 Rapid dissociation, 87–90, 88f, 90f
 Receptor binding properties
 atypical antipsychotics, 87–90, 88f
 conventional antipsychotics, 87f, 87–90
 Retardation, 3–4
 Risperidone, 70–72, 71f
 Ritanserin, 128
- Schizoaffective disorders, 4, 6f, 8f, 9
 Schizophrenia
 aggressive and hostile symptoms, 8f, 9
 cognitive symptoms, 6, 7f
 defined, 2–4
 depressive and anxious symptoms, 8f, 9–10
 dopamine pathways in, 10–16, 11f–15f
 mesocortical dopamine pathway, 10–11, 11f, 13, 13f, 14f
 mesolimbic dopamine pathway, 10, 11f, 12f
 nigrostriatal dopamine pathway, 10, 13–14, 15f
 tuberoinfundibular dopamine pathway, 14–16, 15f
 excitotoxicity and, 22–23, 29f–33f
 experimental therapeutic approaches, 29–33, 33f, 34f
 five symptom dimensions, 4–10, 5f–8f, 9t
 future combination chemotherapies for, 131–132
 in general population, 4
 glutamatergic neurotransmission and, 23–28, 24f–34f
 negative symptoms, 5f, 5–6, 7f, 9t
 neurodegenerative causes of, 21–30, 24f–35f
 neurodegenerative hypotheses of, 21–29
 neurodevelopmental hypothesis of, 16–21, 17f–21f
 novel neurotransmitter mechanisms and, 130–131
 novel serotonergic and dopaminergic mechanisms and, 127–128
 positive symptoms, 4–5, 5f–6f, 9t
 stages of, 21–22, 22f
 treatment in clinical practice, 80–86 (*See also* Antipsychotic agents)
 for cognitive symptoms, 84–85, 84f
 for hostility, aggression, and poor impulse control, 86, 86f
 for mood disorders, 82–84, 83f
 for negative symptoms, 85–86, 85f
 for positive symptoms, 81–82, 82f
 treatment resistant, 124–127, 124f–126f
 Second-messenger system, 102, 103f–108f, 107
 Serial learning, 6
 Serotonergic mechanisms, novel, 127–128
 Serotonin 2A receptors
 binding in cerebral cortex
 atypical antipsychotics, 63f
 conventional antipsychotics, 62f
 improved positive symptoms and, 62–64
 low EPS and, 51, 55–56, 57f–59f, 59
 reduced hyperprolactinemia and, 61–62, 63f–65f
 Serotonin-dopamine antagonism, 51–52, 52f, 55–56, 58f, 59–64, 65f
 serotonergic control of dopamine release, 51–53
 Serotonin-dopamine interactions, in nigrostriatal pathway, 53–54, 53f–58f
 Sexual dysfunction, 16, 44
 Sigma antagonists, 130
 SR 141716A, 130
 SR-142948, 130
 SR31742A, 130
 Stevens-Johnson syndrome, 113
 Stroke, 23, 28, 29f
 Substance P, 130
 Synapses
 formation, 16
 inadequate selection, 17f
 normal formation of, 18f
 wrong connections, 19f
- Tardive dyskinesia
 conventional antipsychotics and, 46, 117, 118f
 D2 receptor blockage and, 43, 43f
 neuroleptic-induced, 14
 Therapeutic approaches in schizophrenia, 29–33. *See also* Schizophrenia
 blocking neurodegeneration and apoptosis, 29–30, 33f, 34f
 combined neurodevelopmental/neurodegenerative hypothesis, 33, 35f
 presymptomatic treatment, 30, 33
 Therapeutics, genetic approach to, 21, 21f
 3-ppp, 96
 Tics, 13
 Topiramate, 113, 115, 116f, 123f
 Toxic insult, 17f
 Tuberoinfundibular dopamine pathway, 14–16, 15f
 Tuberoinfundibular pathway, reduced
 hyperprolactinemia and, 43–44, 44f, 61–62, 63f–65f

Cambridge University Press

978-0-521-89074-8 - Essential Psychopharmacology of Antipsychotics and Mood Stabilizers

Stephen M. Stahl

Index

[More information](#)**142 Index**Twin studies. *See* Genetics

WAY135,452, 96

Weight gain, 44, 49, 49f

Valproic acid, 108, 109t, 111–112, 111f–114f

YM-43611, 128

bipolar combinations and, 119–120, 123f

Verbal fluency, impaired, 6

Vitamin E, 29

Ziprasidone, 73–75, 74f–75f

Voltage-gated ion channels, 100f–101f, 102f–108g,
112f–113f

Zotepine, 127, 129f